Network meta-analysis of 152 RCTs (17431 pts) comparing efficacy of exercise therapy, NSAIDs, Tylenol for knee or hip osteoarthritis: Found all 3 equivalent at 4 wk, 8 wk and 24 wks. https://t.co/rKck2AacL4 https://t.co/YEAMh9UxTs

Remibrutinib in Sjogren's Syndrome Dr. Michael Putman reports on abstract 1113 presented at ACR22. Abstract 1113: Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study https://t.co/4UAxMq2z0X https://t.co/kzinfgDGZr

FDA Accepts Biologics License Application for CT-P13 SC, a Subcutaneous Formulation of Infliximab (Celltrion) that is approved in other countries. https://t.co/G1OIoqk9ga https://t.co/NEWFNlKhlU

Neutrophil-to-lymphocyte ratio (NLR) was studied in 205 Idiopathic pulmonary fibrosis (IPF) pts - NLR correlated with lung function, & outcomes - NLR >= 2.9 was associated with a significant 2 fold increased risk of mortality https://t.co/FCuKx2NfeC https://t.co/iIb9uIGBAE

Rheumatology Giants in who passed away in 2022: Eric Gall William Wilke John Winfield Peter Simkin Roy Altman Samuel Strober James Fries Robert Lightfoot Bart Lindsley https://t.co/BX3fGBVre7 https://t.co/ToxZOZHOhU

For 2023 - what you going to focus on with your patients? Same ole, same ole means youre not getting better. How about focusing on 2 main messages, mine would be patient "STRENGTH" and "COMPLIANCE" (meaning more Rx education) https://t.co/fEIVYk6Z9m

"Taking an idea isn’t theft. Taking an idea is an oxymoron. Ideas belong to all of us" - Seth Godin @ThisIsSethsBlog https://t.co/eY8Tj0c1rF

2022 Rheumatology Year in Review 2022 was a year of recovery, discovery, and some losses. While still dealing with the aftermath of COVID-19, rheumatologists were resilient as leaders for their patients and research in advancing rheumatologic care. https://t.co/L7bUUdHqQF https://t.co/aVSXyzF3yy

According to a 2022 Review of Physician and Advanced Practitioner Recruiting Incentives" by Merritt Hawkins, orthopedics has the highest salary & pediatrics the lowest. Rheumatology: Low: $200,000, Average: $258,000, High: $325,000 https://t.co/PmmAj9s2Vq https://t.co/nEzp4pWiG0

Reuters reports that in 2021, the median annual price was $180,000 for the 1st 30 drugs FDA approved. In 2022, the median annual cost was $222,003 for newly approved drugs. https://t.co/laxw6DacHr https://t.co/kRM7EbrD72

Do not take antacids or PPI with mycophenolate. Magnesium & aluminium hydroxide antacids (Maalox) will lower MMF Cmax 33% & AUC 17% if given simultaneously. PPI also lowers AUC by ~33% https://t.co/qXspeRj0eV https://t.co/g7L2OIgFKc https://t.co/egZFKLbNC7 https://t.co/6M3KIG1kTz